United Therapeutics Corporation (UTHR)

Net profit margin

Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020
Net income (ttm) US$ in thousands 1,195,100 1,110,900 1,069,400 1,050,500 984,800 899,800 871,500 728,300 727,300 707,400 630,800 687,400 475,800 462,400 470,900 405,400 514,800 468,600 429,800 527,800
Revenue (ttm) US$ in thousands 2,877,400 2,756,200 2,616,700 2,498,300 2,327,500 2,204,300 2,110,900 1,981,300 1,936,300 1,860,000 1,788,700 1,768,300 1,685,500 1,655,200 1,590,600 1,506,100 1,483,300 1,409,500 1,430,900 1,442,500
Net profit margin 41.53% 40.31% 40.87% 42.05% 42.31% 40.82% 41.29% 36.76% 37.56% 38.03% 35.27% 38.87% 28.23% 27.94% 29.61% 26.92% 34.71% 33.25% 30.04% 36.59%

December 31, 2024 calculation

Net profit margin = Net income (ttm) ÷ Revenue (ttm)
= $1,195,100K ÷ $2,877,400K
= 41.53%

The net profit margin of United Therapeutics Corporation has shown some fluctuations over the years, ranging from a low of 26.92% in March 2021 to a high of 42.31% in December 2023. Overall, the company has maintained a healthy net profit margin, staying above 30% for most periods. The upward trend in the net profit margin from 2022 to 2024 indicates improving profitability and efficiency in managing costs relative to revenue. Investors and stakeholders may view this positively as it demonstrates the company's ability to generate profits from its operations. However, it is important to continue monitoring the net profit margin to ensure sustained profitability in the long term.